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ABSTRACT
Patients with type 2 diabetes mellitus are at a higher 
risk of developing heart failure compared with the 
healthy population. In recent landmark clinical trials, 
sodium- glucose co- transporter 2 (SGLT2) inhibitor 
therapies improve blood glucose control and also reduce 
cardiovascular events and heart failure hospitalisations 
in patients with type 2 diabetes. Intriguingly, such 
clinical benefits have also been seen in patients with 
heart failure in the absence of type 2 diabetes although 
the underlying mechanisms are not clearly understood. 
Potential pathways include improved glycaemic 
control, diuresis, weight reduction and reduction in 
blood pressure, but none fully explain the observed 
improvements in clinical outcomes. More recently, 
novel mechanisms have been proposed to explain 
these benefits that include improved cardiomyocyte 
calcium handling, enhanced myocardial energetics, 
induced autophagy and reduced epicardial fat. We 
provide an up- to- date review of cardiac- specific SGLT2 
inhibitor–mediated mechanisms and highlight studies 
currently underway investigating some of the proposed 
mechanisms of action in cardiovascular health and 
disease.
INTRODUCTION
Heart failure is a global pandemic and the current 
worldwide prevalence of heart failure is estimated 
at 64.34 million cases accounting for 9.91 million 
years lost due to disability.1 The prevalence of 
heart failure increases with age and is associated 
with other comorbidities like type 2 diabetes 
mellitus, hypertension and obesity. People with 
type 2 diabetes are 2.5 times more likely to develop 
cardiac failure than people without diabetes.2 
Concerns regarding cardiovascular adverse events 
associated with type 2 diabetes have convention-
ally focused around atherosclerotic events, but with 
major improvements in the treatment of myocar-
dial infarction, stroke and limb ischaemia over the 
past few decades, heart failure is increasingly being 
recognised as one of its earliest and most serious 
complications.3
The problems of heart failure associated with 
diabetes are compounded by the fact that several 
therapeutic glucose- lowering agents are either 
ineffective or harmful. Thiazolidinediones, such 
as pioglitazone, activate peroxisome proliferator- 
activated receptor gamma (PPAR gamma) to 
improve insulin sensitivity. However, they also 
cause increased sodium and fluid retention, thereby 
leading to a 42% increased risk of incident heart 
failure.4 In contrast, dipeptidyl peptidase 4 inhib-
itors appear to have a neutral effect on major 
adverse cardiovascular events although one agent 
of this class, saxagliptin, has been associated with 
a 27% increase in hospitalisation for heart failure 
and a 22% increase in cardiovascular mortality.5 
A meta- analysis of more than 24 000 individuals 
from four large clinical trials reported that the 
use of insulin for type 2 diabetes was associated 
with a 27% increase in all- cause mortality and 
23% increase in hospitalisation for heart failure.6 
Looking at 100 000 individuals in the ‘real- world’ 
setting of an administrative database, such treat-
ment was associated with an odds ratio of 2.02 for 
all- cause mortality and 1.42 for heart failure hospi-
talisation.6 Therefore, there is an unmet need for 
safer and more effective glucose- lowering therapies 
for patients with type 2 diabetes and heart failure.
Sodium-glucose co-transporter 2 inhibitor 
therapy
Sodium- glucose co- transporter 2 (SGLT2) inhibi-
tors are a new class of glucose- lowering drugs. They 
work by blocking the low- affinity, high- capacity 
SGLT2 protein located in the proximal convo-
luted tubule of the nephron. The SGLT2 protein 
is responsible for the resorption of approximately 
90% of filtered glucose while the remainder is 
reabsorbed by SGLT1 proteins found on the distal 
part of the proximal convoluted tubule. SGLT2 
inhibition results in glycosuria (and natriuresis as 
the protein is a co- transporter), thereby lowering 
plasma glucose concentrations.7 8 This mechanism 
is unique compared with all other glucose- lowering 
agents as it does not interfere with endogenous 
insulin or incretin pathways.
In recent cardiovascular outcome trials, SGLT2 
inhibitors are associated with 30%–35% lower 
risk of hospitalisation for heart failure.9–12 Other 
glucose- lowering agents appear to be more potent 
than SGLT2 inhibitors, but fail to reduce cardiovas-
cular risk, particularly with regard to heart failure 
outcomes. Moreover, although the glucose- lowering 
efficacy of SGLT2- inhibitor therapy declines at 
lower estimated glomerular filtration rates, its 
cardiovascular benefits are remarkably preserved, 
even in patients with renal impairment. This implies 
differing mechanisms of action in glycaemic control 
and cardiovascular risk reduction.13 These potential 
cardioprotective mechanisms remain incompletely 
understood and we aim to describe some of the key 
theories (table 1) in this review as this could pave 
the way for targeting future novel therapies for 
both heart failure and type 2 diabetes.
SGLT2 inhibitor therapy and cardiovascular 
outcomes
In response to concerns about the increased cardio-
vascular risk associated with some treatments for 
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diabetes, regulators in the USA and Europe mandated cardio-
vascular safety trials of all new hypoglycaemic drugs in 2008. In 
recent cardiovascular outcome trials, the glucagon- like peptide 
1 receptor agonist (GLP-1 RA) and SGLT2 inhibitors have 
demonstrated reductions in cardiovascular events, reversing 
the trend of previous therapies. While the benefits with GLP- 
1RAs are associated with reduced atherothrombotic events like 
myocardial infarction and stroke,14 SGLT2- inhibitor therapies 
have demonstrated improved outcomes in heart failure9 10 15 
(table 2). Interestingly, the reduction in heart failure hospitalisa-
tion was observed within months of randomisation, suggesting 
a different mechanism of effect from those of other glucose- 
lowering drugs which usually takes years to manifest.9–12 The 
consistent signal of improved heart failure outcomes in the early 
trials led to the ‘Dapagliflozin in Patients with Heart Failure and 
Reduced Ejection Fraction’ (DAPA- HF trial) which was specif-
ically designed to evaluate the efficacy of the SGLT2- inhibitor 
therapy in patients with heart failure and a reduced ejection frac-
tion, regardless of the presence or absence of diabetes. This trial 
showed that dapagliflozin reduces the risk of worsening heart 
failure or death from cardiovascular causes by 26%, regardless of 
diabetes status, suggesting that these benefits are independent of 
the drug’s glucose- lowering effect.15' More recently, results from 
the ‘Empagliflozin outcome trial in patients with chronic heart 
failure with reduced ejection fraction’ (EMPEROR- Reduced) 
trial showed that empagliflozin also reduced the composite 
risk of cardiovascular death and heart failure hospitalisation in 
patients with known heart failure with reduced ejection frac-
tion regardless of diabetes status.16 In both of these trials, the 
risk reduction seen in their primary outcomes was principally 
driven by a reduction in hospitalisations for heart failure.15 16 
Meta- analysis of these two trials shows consistency of effect of 
both dapagliflozin and empagliflozin with reductions in all the 
individual endpoints of all- cause death, cardiovascular death, 
hospitalisation for heart failure or decline in renal function.17 
Thus, these striking benefits appear to be a class effect of SGLT2- 
inhibitor therapies. So, what is the mechanism of these marked 
benefits?
Conventional potential mechanisms of benefit with SGLT2 
inhibition
The desirable cardiovascular effects seen with SGLT2 inhibitor 
treatment may be multifactorial, but key pathways involved are 
currently being explored. Some of the conventional theories are 
discussed in the following section.
Diuretic and antihypertensive effects
It has been suggested that SGLT2 inhibitors improve cardio-
vascular outcomes due to their diuretic and antihypertensive 
effects (figure 1). SGLT2 inhibitors cause osmotic diuresis due 
to glucosuria and natriuresis, although the degree of diuresis and 
its composition (ie, the amount of natriuresis compared with 
aquaresis) remains to be established.18 Indeed, in the context of 
co- administration of loop diuretic therapies, the contribution 
of osmotic diuresis towards improved heart failure outcomes 
remains unclear. Glycosuria in the context of SGLT2- inhibitor 
therapy administration occurs due to a twofold to threefold 
increase in the filtered and resorbed glucose in presence of 
hyperglycaemia. Therefore, glycosuria and osmotic diuresis 
associated with SGLT2 inhibition are dependent on blood 
glucose concentrations and hence this does not explain the 
similar benefits observed in normoglycaemic patients with heart 
failure in the absence of diabetes mellitus.15 16 Although SGLT2- 
inhibitor therapy is associated with natriuresis and reduction in 
plasma volume,9 19 it is unclear if these benefits are sustained as 
there were no differences seen in serum N- terminal pro B- type 
natriuretic peptide (NT- pro BNP) concentrations in patients 
with chronic stable heart failure despite improvements in heart 
failure status.20 Moreover, there was no change in the diuretic 
dose among most participants during follow- up in the DAPA- HF 
trial, and the mean diuretic dose was similar between dapagli-
flozin and placebo groups.15
Recent studies have highlighted important differences between 
the diuretic effect of SGLT2 inhibitors and loop diuretic thera-
pies. Using mathematical modelling, a recent study showed that 
both dapagliflozin and bumetanide were associated with a reduc-
tion in sodium and interstitial fluid. However, dapagliflozin had 
little or no effect on plasma volume whereas bumetanide was 
associated with reductions in intravascular volume, which can 
pose challenges in the context of hypoperfusion.21 This predicted 
selectivity of SGLT2 inhibitors for interstitial fluid is supported 
by observations from ‘the renal and cardiovascular effects of 
SGLT2 inhibition in combination with loop diuretics in patients 
with type 2 diabetes and chronic heart failure’ (RECEDE- CHF) 
trial which showed an average increase in daily urine volume 
of 545 mL, 312 mL of which was electrolyte- free water clear-
ance.22 This may suggest a synergistic effect of SGLT2- inhibitor 
therapy with background diuretic treatment in heart failure. 
This, however, requires further validation.
The antihypertensive effect associated with SGLT2 inhibition 
was previously thought to be secondary to diuresis and natri-
uresis, but given that this effect is preserved even with declining 
glomerular filtration rates, it has been suggested to be more 
likely secondary to improved endothelial function, reduced 
arterial stiffness and changes in sympathetic nervous activity as 
evidenced by recent studies.23 24 A recent meta- analysis reported 
only a modest overall antihypertensive effect from SGLT2 inhi-
bition: pooled estimate reduction of 2.46/1.46 mm Hg in blood 
pressure.25 This degree of reduction in blood pressure, although 
salutary in the context of cardiovascular disease, is also unlikely 
to be responsible for the striking benefits in cardiovascular 
morbidity and mortality.
Weight reduction and improved glycaemic control
It has been postulated that weight reduction and improved 
glycaemic control underlie the cardioprotective effect seen with 
SGLT2- inhibitor therapy. However, there are key considerations 
worthy of discussion. Weight loss from SGLT2- inhibitor therapy 
occurs due to an increased glucagon:insulin ratio causing 
increased lipid mobilisation and is thought to be one of the mech-
anisms involved in reduction in heart failure mortality associated 
with SGLT2- inhibitor therapy.26 27 Up to 2.7 kg weight loss was 
observed in patients with type 2 diabetes with SGLT2- inhibitor 
therapy, and there are some studies suggesting weight loss in pre- 
diabetic patients.28 29 However, there is currently no evidence to 
suggest that it can cause weight loss in patients with heart failure 
Table 1 Potential mechanisms of cardiovascular benefits associated 
with SGLT2- inhibitor therapy
Conventional mechanisms Novel mechanisms
Diuresis and reduction in blood pressure Improved myocardial energetics
Improved glycaemic control Improved myocardial ionic homeostasis
Weight loss Autophagy
Increase in red blood cell mass and 
haematocrit
Altered adipokine regulation
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in the absence of diabetes which would be an argument against 
weight reduction being the primary mechanism of benefit with 
SGLT2- inhibitor therapy. Moreover, despite the high preva-
lence of obesity in heart failure, there is little definitive evidence 
regarding the impact of weight loss on cardiac function, quality 
of life and exercise tolerance in patients with heart failure.30 
Therefore, weight loss alone cannot explain SGLT2 inhibition–
related benefits in heart failure.
Increase in haematocrit
SGLT2- inhibitor therapy is associated with increases in renal 
erythropoietin production, red blood cell mass and haemato-
crit.27 Such changes may contribute to improvements in cardio-
vascular outcomes although similar increases in haematocrit have 
been reported with darbepoetin alfa and no mortality benefit was 
observed in patients with left ventricular systolic dysfunction.31
Overall, many of these mechanisms and recognised factors have 
been associated with reductions in cardiovascular risk (figure 1). 
However, the modest improvements seen with SGLT2- inhibitor 
therapy in these domains do not provide a clear explanation for 
the striking benefits observed in heart failure events in the large 
clinical trials and key pathways involved still require further 
investigation.
Novel potential mechanisms of benefit with SGLT2 inhibition
Direct cardiac effects of SGLT2-inhibitor therapy
Cardiac hypertrophy, fibrosis and inflammation lead to adverse 
cardiac remodelling in heart failure, and this is a key contributor 
to its severity.32 Some pre- clinical and clinical studies have demon-
strated a role for SGLT2- inhibitor therapies in reversing adverse 
cardiac remodelling.33 34 Although this effect has been observed 
in patients with type 2 diabetes and left ventricular hypertrophy, 
it has not been seen in patients with heart failure.35 36 This is 
intriguing, particularly, since the majority of its cardiovascular 
benefits have been around heart failure outcomes. This raises the 
possibility that, in the context of heart failure, SGLT2 inhibition 
may have novel direct cardioprotective effects, beyond that of 
ventricular loading and remodelling (figure 2).
Improved myocardial energetics
Under physiological conditions, nearly 90% of cardiac energy 
is derived from mitochondrial oxidative metabolism and fuel is 
derived from free fatty acids, glucose and to a lesser extent from 
lactate, ketones and amino acids.37 In type 2 diabetes or heart 
failure, there is dysregulated fatty acid oxidation and impaired 
glucose uptake or oxidation causing myocardial dysfunction. In 
this setting of restricted fuel selection and low energetic reserve, 
ketone bodies are a ‘super- fuel’, producing ATP more effi-
ciently than glucose or free fatty acids. SGLT2- inhibitor therapy 
increases hepatic synthesis and decreases the urinary excretion 
of ketones producing a mild and persistent state of hyperket-
onaemia. Under these conditions, beta- hydroxybutyrate (ketone 
body) is freely taken up by the heart and kidney and oxidised 
in preference to fatty acids and glucose. In mouse hearts, beta- 
hydroxybutyrate increases external cardiac work and reduces 
oxygen consumption, thereby improving cardiac efficiency.38 
It has thus been hypothesised that the cardiovascular benefits 
of SGLT2- inhibitor therapy may be related to a shift in cardiac 
metabolism away from fatty acids and glucose oxidation towards 
more oxygen- efficient ketone bodies, thereby improving cardiac 
efficiency.
Improved ionic homeostasis in the myocardium
Calcium homeostasis in the myocardium is a finely balanced 
mechanism, essential for efficient excitation–contraction 
coupling.39 During systole, calcium is actively transported into 
the cardiomyocyte via L- type voltage- gated calcium channels 
where it binds to ryanodine receptors on the sarcoplasmic retic-
ulum resulting in ‘calcium- induced calcium release’. This, in 
turn, activates calcium- sensitive contractile proteins (troponin 
C, troponin NC) which leads to myocardial contraction. In the 
setting of type 2 diabetes and heart failure, there is upregulation 
Figure 1 Schematic diagram showing conventional mechanisms of action of SGLT2 inhibitors. SGLT, sodium- glucose co- transporter.
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of both sodium- hydrogen exchanger 1 and SGLT1 resulting in 
markedly increased intra- cytosolic sodium content.40 41 This 
promotes calcium influx via the membrane bound sodium–
calcium exchanger transporters and calcium efflux from the 
mitochondria (into the cytosol) via mitochondrial sodium–
calcium exchanger transporters. The elevated baseline intracel-
lular calcium content results in reduced calcium transients and 
smaller sarcoplasmic reticulum calcium stores in diabetic cardio-
myocytes, thereby inhibiting contractile function.42
SGLT2- inhibitor therapy reduces cardiac cytosolic sodium 
content by inhibiting sodium- hydrogen exchanger 1 and SGLT1 
transporters in diabetic rat and mice myocytes, thereby reversing 
calcium overload.42–47 Intriguingly, this effect on sodium- 
hydrogen exchanger 1 and SGLT1 is independent of diabetes 
status.48 These findings suggest that altered myocardial calcium 
handling is involved in the development of diabetic cardiomy-
opathy and heart failure, and that SGLT2- inhibitor therapy 
may improve the electrochemical characteristics in the failing 
myocardium which may contribute to its cardiovascular benefit. 
An ongoing clinical trial will assess the role of altered calcium 
handling in diabetic cardiomyopathy and heart failure and 
determine the effects of SGLT2- inhibitor therapy on cardiac 
calcium homeostasis (NCT04591639). The study uses a novel 
imaging approach called manganese- enhanced magnetic reso-
nance imaging (MRI). Manganese acts as a calcium analogue and 
administration of the manganese- based contrast agent results in 
a marked shortening of the T1 relaxation times in myocardium 
with intact calcium handling. The rate of T1 shortening there-
fore acts as a measure of myocardial calcium handling, and this 
is the primary endpoint of the study.
Autophagy
Autophagy is the process by which cellular physiological equi-
librium is maintained by removal of potentially dangerous 
constituents and recycling of cellular components as an adap-
tive response to metabolic stress including hypoxia and 
starvation.49 Experimental induction of autophagy has favour-
able effects in heart failure as it leads to efficient disposal of 
dysfunctional mitochondria, which are a major source of reac-
tive oxygen species, promoting oxidative stress and inflamma-
tion.50 The pathways of autophagy induction involve activation 
of adenosine monophosphate- activated protein kinase (AMPK), 
sirtuin-1 (SIRT1) and hypoxia- inducible factors (HIF- 1alfa and 
HIF- 2alfa).51 It has been proposed that SGLT2 inhibitors may 
induce autophagy by simulating nutrient depletion by periods of 
increased catabolism due to constant glucosuria. Indeed, various 
SGLT2- inhibitor therapies have upregulated the expression of 
AMPK, SIRT1 and HIF-1 alfa.52 53 These actions might explain 
the phenomenon of autophagy and associated cardiovascular 
benefits with SGLT2- inhibitor therapy.54
Altered adipokine regulation
Leptin and adiponectin are cytokines produced exclusively by 
adipocytes. These ‘adipokines’ are essential in the regulation 
of food intake and energy homeostasis with leptin being impli-
cated in various obesity- related cardiovascular diseases, whereas 
adiponectin is considered cardioprotective.55 Epicardial fat depo-
sition due to altered adiponectin and leptin regulation is one of 
the theories implicated in the development of heart failure.56 
Increased serum leptin concentrations are seen in patients with 
heart failure and they are associated with cardiac remodelling 
due to cardiac fibrosis and inflammation.57
SGLT2 inhibition reduces serum leptin and increases 
adiponectin concentrations, potentially offering some cardio-
protection.58 However, these effects may well be reflective of 
changes secondary to the systemic effects of SGLT2- inhibitor 
therapy including weight loss and lipolysis.
Future directions
The exact pathways of cardiovascular benefit with SGLT2- 
inhibitor therapy are yet to be established and newer mecha-
nisms may emerge over time. It is plausible that SGLT2 inhibition 
interacts with or mediates other key pathways at a cellular level, 
facilitating cardiovascular benefits. Thus, establishing the exact 
mechanism of benefit is key to understanding the benefits of 
Figure 2 Schematic diagram showing proposed novel mechanisms of action of SGLT2 inhibitors in heart failure. AMPK, adenosine monophosphate- 
activated protein kinase; HIF, hypoxia- inducible factor; NHE, sodium- hydrogen exchanger; SGLT, sodium- glucose co- transporter; SIRT, sirtuin.
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SGLT2 inhibition and may also open up new and unexplored 
pathways which could provide rich avenues of understanding 
for the pathophysiology and potential future novel treatments 
of heart failure.
There are several ongoing clinical studies investigating the 
mechanisms of cardiovascular benefits with SGLT2 inhibition 
such as the effects on cardiac remodelling (NCT03871621), 
lipolysis and modification of epicardial fat thickness and prop-
erties (NCT04219124, NCT04167761 and NCT02235298), 
myocardial calcium handling (NCT04591639) and endogenous 
ketone production (NCT03852901, NCT04219124).
These studies will provide significant insights into the key 
pathways involved in the cardioprotective effects associated with 
SGLT2- inhibitor therapy.
CONCLUSIONS
SGLT2- inhibitor therapies are a promising new class of drugs for 
treating type 2 diabetes and heart failure. The cardioprotective 
effect of SGLT2 inhibition has been demonstrated in models of 
diabetic cardiomyopathy, heart failure and ischaemic cardiomy-
opathy. The mechanism through which SGLT2- inhibitor therapy 
exerts its benefit in patients with heart failure remains incom-
pletely understood. It is possible that a combination of systemic 
and direct effects of SGLT2 inhibition on the myocardium ulti-
mately leads to the cardiovascular benefits. However, there is 
strong pre- clinical evidence to suggest that improved myocardial 
ionic homeostasis has a role to play with regards to the cardio-
vascular benefits seen with SGLT2- inhibitor therapy. Studies 
examining the mechanistic role of SGLT2 inhibitor therapy in 
cardiovascular health will be instrumental in shaping our under-
standing of heart failure and diabetic cardiomyopathy and may 
open avenues for the development of future drug therapies that 
target these pathways.
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